FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with standard first-line therapy to enhance the anti-tumor immune effect at the same time, thereby extending the progression-free survival of patients and improving the prognosis of patients.

Trial Details

NCT ID

NCT06403111

Phase

PHASE2

Sponsor

Changzhou No.2 People's Hospital

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy

Locations (sample)

Changzhou, China|31.77359,119.95401

Key Eligibility Criteria

The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;
Age 18-80 years old (when signing the informed consent form);
Patients with histologically or cytologically proven locally advanced (stage IIIB/IIIC), metastatic, or recurrent (stage IV) NSCLC who are inoperab…
Have not received systemic intravenous anti-tumor therapy before, and the driver gene is negative;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →